Background Although the increased risk of cardiovascular disease in patients with SLE is well-documented, effective tools for risk stratification remain elusive. This study sought to explore the ...

Objective Biologics for systemic lupus erythematosus (SLE) demonstrate variable treatment responses across trials. We evaluated baseline biomarkers as predictors of response to guide personalised ...

Objectives Moderate BILAG-2004 flare definitions are less well validated than severe flare definitions, and moderate flares are reported less frequently in clinical trials. Moderate flares may be ...

Objectives A few clinical trials have been performed studying Bruton’s tyrosine kinase (BTK) inhibitors in patients with systemic lupus erythematous (SLE). We evaluate the literature and evidence to ...

Objectives Ianalumab is an afucosylated, fully human IgG1 monoclonal antibody targeting B-cells through a novel dual mechanism of action of enhanced B-cell depletion through antibody-dependent ...

Objectives Cutaneous lupus erythematosus (CLE) is a chronic inflammatory skin condition with no approved targeted treatments. Afimetoran – a first-in-class, once daily oral, selective, equipotent, ...

Objectives Lupus Research Alliance (LRA) developed a Biomarker Roadmap, with the goal of creating a more focused and impactful approach to biomarker development in lupus. The roadmap outlines a ...

Objectives The current lack of accepted definitions of at-risk populations for inclusion in research studies and trials is a substantial roadblock to testing SLE prevention strategies. We are ...

Objectives Belimumab (BEL), a B-cell modulator mAb that selectively inhibits soluble B-lymphocyte stimulator and reduces autoreactive B cells driving lupus disease activity, is approved for adult and ...

Objectives Antibody-secreting cells (ASC) produce autoantibodies in Systemic Lupus erythematosus (SLE), thereby contributing to the pathogenesis. Some ASC are long-lived and resistant to standard ...

Objectives Platelets have been proposed both as effector cells in the pathogenesis of SLE and as targets of autoimmune phenomena during the disease course. Thrombocytopenia has been reported in 20–40% ...

Objectives Complement activation plays a dual role in systemic lupus erythematosus (SLE) and lupus nephritis (LN) pathogenesis: protective through clearance of immune complexes and cellular waste, but ...